ALK+弥漫大B 细胞淋巴瘤患者临床决策探讨*

Clinical decision on a patient with ALK+ diffuse large B cell lymphoma

    摘要
  • 摘要: ALK+弥漫大B 细胞淋巴瘤（anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma ，ALK+DLBCL ）是淋巴瘤中一种罕见的和具有明显差异性的病理类型，2008年WHO将其归类为DLBCL 一个独特的亚型，该病侵袭性高，容易复发，目前尚无规范有效的治疗方案。采取多学科协作体系（multidisciplinary treatment ，MDT ）有利于制定规范化、个体化的治疗方案，探索针对ALK+DLBCL 患者更有效的治疗方法，从而让更多的患者获益。本研究分享1 例2012年1 月天津医科大学肿瘤医院收治的ALK+DLBCL 高剂量化疗联合自体造血干细胞移植（autologous hematopoietic stem cell transplantation ，AHSCT）后复发，采用ALK 激酶抑制剂克唑替尼（Crizotinib ）治疗成功的案例。

     

    Abstract: Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008WHO classification of lymphomas. No standard and effective therapeutic regi -men is available for ALK +DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This arti -cle presents a case of an ALK+ DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibi-tor Crizotinib.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回